A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes

NCT02119819 on ClinicalTrials.gov · last registry update 2021-05-27

An unusually large phase 2: 420 participants, more than double the 110 typical for the stage. The sponsor logged completion for August 2015. Primary outcome, as filed: Change From Baseline in Hemoglobin A1c (HbA1c) at Week 12. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P2
Drug: exenatide
Bydureon, Byetta
Sponsor: OPKO Health, Inc.
Sponsor type: Industry
Enrollment: 420
Started: 2014-04
Primary completion: 2015-08 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change From Baseline in Hemoglobin A1c (HbA1c) at Week 12

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.